Investor Update

Basel, 15 August 2011

Roche Investor Science Event from ESC 2011: Phase II data from the endothelial function study dal-VESSEL and the imaging study dal-PLAQUE

Monday, 29 August 2011, Paris, France

We kindly invite investors and analysts to participate in a conference call that will be held during the European Society of Cardiology Congress taking place from 27-31 August 2011 in Paris.

On the call, Roche will discuss new data from two phase IIb studies with the CETP modulator dalcetrapib. The studies investigated dalcetrapib’s effects on vascular function (dal-VESSEL) and on atherosclerotic disease progression (dal-PLAQUE). Further, Roche will provide an overall update on the CardioMetabolism franchise. The presentation will be followed by a Q&A session.

The conference call will take place on:

Investors and analysts are invited to join the conference call either by live audio webcast or by telephone.

Live audio webcast

The live conference call can be accessed via Following the event, an MP3 file will be made available for download.

Phone conference call

The live conference call can be accessed using the following dial-in numbers:

Please dial in to the conference call 10 – 15 minutes before the call is scheduled to start.
+41 91 610 56 00 (Europe)
+44 203 059 58 62 (UK)
+1 866 291 41 66 (USA - Toll-Free)

A replay of the conference call will be available one hour after the conference call and then for 48 hours. The replay can be accessed using the following dial-in numbers:

+41 91 612 4330 (Switzerland)
+44 207 108 6233 (UK)
+1 866 416 2558 (USA)
Enter the ID 18878 followed by the # sign

At the time of the conference call, the accompanying presentation will be available from the IR website at